Liverpool HIV Interactions

Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

No Interaction Expected

Emtricitabine/Tenofovir alafenamide (FTC/TAF)

Dolutegravir (DTG)

Quality of Evidence: Low

Summary:

Coadministration of dolutegravir (50 mg once daily) with emtricitabine/tenofovir alafenamide (200/10 mg, once daily) increased tenofovir AUC and Cmax by 25% and 10% (n=10). No significant effects were observed on dolutegravir pharmacokinetics relative to historical controls. Coadministration of dolutegravir (50 mg once daily) and tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat (10/200/150/150 mg) had no significant effect on the pharmacokinetics of dolutegravir and tenofovir alafenamide. The recommended dose of Descovy for HIV-1 treatment is 200/25 mg once daily.

Description:

When given with dolutegravir for HIV-1 treatment, the dose of Descovy is 200/25 mg once daily. Coadministration of dolutegravir (50 mg once daily) and tenofovir alafenamide (10 mg once daily, given as elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet) had no effect on the AUC and Cmax of tenofovir alafenamide, nor on the AUC, Cmax and Cmin of dolutegravir.

Descovy Summary of Product Characteristics, Gilead Sciences Ltd, April 2022.

Based on drug interaction studies conducted with the components of Descovy, no clinically significant drug interactions have been either observed or are expected when Descovy is combined with dolutegravir. Coadministration of dolutegravir (50 mg once daily) and tenofovir alafenamide (10 mg once daily) was studied in 10 subjects. Tenofovir alafenamide Cmax and AUC increased by 24% and 19%; dolutegravir Cmax, AUC and Cmin increased by 15%, 2% and 5%, respectively.

Descovy US Prescribing Information, Gilead Sciences Inc, January 2022.

Coadministration of dolutegravir (50 mg once daily) with emtricitabine/tenofovir alafenamide (200/10 mg, once daily) was studied in 10 healthy volunteers in a crossover study. Tenofovir alafenamide AUC and Cmax increased by 17% and 24%, respectively. Tenofovir AUC and Cmax increased by 25% and 10%, respectively. Dolutegravir pharmacokinetic parameters were similar to historical controls.

Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals. Begley R, Das M, Zhong L, et al. J Acquir Immune Defic Syndr, 2018, 78(4): 465-472.

View all available interactions with Emtricitabine/Tenofovir alafenamide (FTC/TAF) by clicking here.